Stock Events

Stock Events

Adaptimmune Therapeutics 

$0.054900
157
-$0.01-15.15% Monday 20:00
+$0.00+5.46%Monday 23:59Pre-market

Statistics

Day High
0.0549
Day Low
0.0549
52W High
0.8334
52W Low
0.0202
Volume
48,742,230
Avg. Volume
102,347,850
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13MayExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
-0.24
-0.08
0.08
0.24
Expected EPS
-0.17
Actual EPS
-0.03

Financials

-39.78%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
178.03MRevenue
-70.81MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is involved in the development of cellular therapy products for cancer, directly competing with Adaptimmune's focus on T-cell therapy for cancer treatment.
Novartis
NVS
Mkt Cap304.1B
Novartis is a major player in the CAR-T cell therapy market with its approved products, competing with Adaptimmune's focus on similar cancer treatments.
Allogene Therapeutics
ALLO
Mkt Cap680.62M
Allogene Therapeutics is focused on the development of allogeneic CAR-T therapies, which could compete with Adaptimmune's autologous T-cell therapy approach.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a broad oncology portfolio, including investments in immunotherapies that could compete with Adaptimmune's T-cell based therapies.
Merck
MRK
Mkt Cap370.89B
Merck & Co. is heavily involved in cancer immunotherapy with its blockbuster drug Keytruda and is expanding into cellular therapies, potentially competing with Adaptimmune.

About

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Show more...
CEO
Mr. Adrian G. Rawcliffe
Employees
506
Country
United Kingdom
ISIN
US00653A1079

Listings

MU
DE
473A.MU
STU
DE
473A.STU
OTC Link
US
ADAPY

0 Comments

Share your thoughts

FAQ

What is Adaptimmune Therapeutics stock price today?▼
The current price of ADAP is $0.05 USD — it has decreased by -15.15% in the past 24 hours. Watch Adaptimmune Therapeutics stock price performance more closely on the chart.
What is Adaptimmune Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Adaptimmune Therapeutics stocks are traded under the ticker ADAP.
Is Adaptimmune Therapeutics stock price growing?▼
ADAP stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Adaptimmune Therapeutics has showed a +29.18% increase.
What were Adaptimmune Therapeutics earnings last quarter?▼
ADAP earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.17 USD resulting in a +82.35% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adaptimmune Therapeutics revenue for the last year?▼
Adaptimmune Therapeutics revenue for the last year amounts to 178.03M USD.
What is Adaptimmune Therapeutics net income for the last year?▼
ADAP net income for the last year is -70.81M USD.
How many employees does Adaptimmune Therapeutics have?▼
As of September 08, 2026, the company has 506 employees.
In which sector is Adaptimmune Therapeutics located?▼
Adaptimmune Therapeutics operates in the Health & Wellness sector.
When did Adaptimmune Therapeutics complete a stock split?▼
The last stock split for Adaptimmune Therapeutics was on March 31, 2000 with a ratio of 2:1.
Where is Adaptimmune Therapeutics headquartered?▼
Adaptimmune Therapeutics is headquartered in Abingdon, United Kingdom.